| Budget Amount *help |
¥17,420,000 (Direct Cost: ¥13,400,000、Indirect Cost: ¥4,020,000)
Fiscal Year 2020: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2019: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2018: ¥6,500,000 (Direct Cost: ¥5,000,000、Indirect Cost: ¥1,500,000)
|
|---|
| Outline of Final Research Achievements |
The xenotransplantation system using immunodeficient mice, which was developed as an assay system for normal human hematopoietic stem cells, is a model for reproducing human diseases, such as stem cell purification and pathological elucidation of hematopoietic tumors and solid tumors, development of stem cell target therapy, and infection experiment model.We aimed to develop a next-generation patient-derived xenograft model that overcomes the problems of the current xenotransplantation system. In the B6 background, we introduced the Kit mutation for bone marrow niche opening and human SIPRA knock-in into Rag2 deficiency and IL2Rg deficiency, and established BRGhSK, which is the completed form of the next-generation PDX model.
|
